Indian Council of Medical Research. Consensus Document for Management of Retinoblastoma. 2023. Available at: https://main.icmr.nic.in/sites/default/files/whats_new/Draft_Consensus_Document_for_Management_of_Retinoblastoma.pdf. Accessed on 22 Jan 2024.

Meel R, Radhakrishnan V, Bakhshi S. Current therapy and recent advances in the management of retinoblastoma. Indian J Med Paediatr Oncol. 2012;33:80–8.

Article  PubMed  PubMed Central  Google Scholar 

Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68:2356–65.

Article  PubMed  PubMed Central  Google Scholar 

Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.

Article  PubMed  Google Scholar 

Novetsky DE, Abramson DH, Kim JW, Dunkel IJ. Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies—an analysis of impact. Ophthalmic Genet. 2009;30:40–4.

Article  PubMed  Google Scholar 

Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829–37.

Article  PubMed  Google Scholar 

Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol. 2001;119:1269–72.

Article  CAS  PubMed  Google Scholar 

Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1988;95:1583–7.

Article  CAS  PubMed  Google Scholar 

Singh U, Katoch D, Kaur S, Dogra MR, Bansal D, Kapoor R. Retinoblastoma: a sixteen-year review of the presentation, treatment, and outcome from a tertiary care institute in northern India. Ocul Oncol Pathol. 2017;4:23–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaliki S, Patel A, Iram S, Ramappa G, Mohamed A, Palkonda VAR. Retinoblastoma in India: clinical presentation and outcome in 1,457 patients (2,074 eyes). Retina. 2019;39:379–91.

Article  PubMed  Google Scholar 

Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453–60.

Article  PubMed  Google Scholar 

Meel R, Bakhshi S, Pushker N, Vishnubhatla S. Randomized, controlled trial in groups C and D retinoblastoma. Ophthalmology. 2015;122:433–5.

Article  PubMed  Google Scholar 

Berry JL, Munier FL, Gallie BL, et al. Response criteria for intraocular retinoblastoma: RB-RECIST. Pediatr Blood Cancer. 2021;68:e28964.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fabian ID, Stacey AW, Johnson KC, et al. Primary enucleation for group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining an eye. Br J Ophthalmol. 2018;102:265–71.

Article  PubMed  Google Scholar 

Scelfo C, Francis JH, Khetan V, et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol. 2017;10:961–7.

PubMed  PubMed Central  Google Scholar 

Kiratli H, Koç İ, Inam O, Varan A, Akyüz C. Retrospective analysis of primarily treated group D retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2018;256:2225–31.

Article  PubMed  Google Scholar 

Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398–404.

Article  PubMed  Google Scholar 

Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017. https://doi.org/10.1002/pbc.26696.

Article  PubMed  PubMed Central  Google Scholar 

Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapyin 76 eyes. Ophthalmology. 2009;116:544–51.

Article  PubMed  Google Scholar 

Rao R, Honavar SG, Reddy VP. Preservation of retinoblastoma group E eyes with neovascular glaucoma using intravenous chemotherapy: risk factors and outcomes. Br J Ophthalmol. 2019;103:1856–61.

PubMed  Google Scholar 

Weng PY, Chen SH, Kao LY, et al. Clinical spectrum and treatment outcome of retinoblastoma with Group D and E diseases: a single institution retrospective review. Medicine. 2020;99:e22201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Temming P, Viehmann A, Biewald E, Lohmann DR. Sporadic unilateral retinoblastoma or first sign of bilateral disease? Br J Ophthalmol. 2013;97:475–80.

Article  PubMed  Google Scholar 

Abramson DH, Servodidio CA. Retinoblastoma in the first year of life. Ophthalmic Paediatr Genet. 1992;13:191–203.

Article  CAS  PubMed  Google Scholar 

Hussain Z. Impact of laterality on cumulative survival in patients diagnosed with retinoblastoma: a retrospective cohort analysis of 1925 cases in the surveillance, epidemiology, and end results (SEER) program. Clin Ophthalmol. 2021;15:991–1001.

Article  PubMed  PubMed Central  Google Scholar 

Meel R, Kashyap S, Bakhshi S, Bajaj MS, Wadhwani M. Retinoblastoma in children older than 6 years of age. Ocul Oncol Pathol. 2020;6:395–404.

Article  PubMed  PubMed Central  Google Scholar 

Kashyap S, Meel R, Pushker N, et al. Phthisis bulbi in retinoblastoma. Clin Exp Ophthalmol. 2011;39:105–10.

Article  PubMed  Google Scholar 

Mallipatna AC, Sutherland JE, Gallie BL, Chan H, Héon E. Management and outcome of unilateral retinoblastoma. J AAPOS. 2009;13:546–50.

Article  PubMed  Google Scholar 

El Zomor H, Nour R, Saad A, et al. Unilateral retinoblastoma; natural history and an age-based protocol in 248 patients. Eye (Lond). 2021;35:2564–72.

Article  PubMed  Google Scholar 

Pérez V, Sampor C, Rey G, et al. Treatment of nonmetastatic unilateral retinoblastoma in children. JAMA Ophthalmol. 2018;136:747–52.

Article  PubMed  PubMed Central  Google Scholar 

Fabian ID, Shah V, Kapelushnik N, et al. Examinations under anaesthesia as a measure of disease burden in unilateral retinoblastoma: the London experience. Br J Ophthalmol. 2020;104:17–22.

Article  PubMed  Google Scholar 

Chantada G, Luna-Fineman S, Sitorus RS, et al; SIOP-PODC Graduated-Intensity Retinoblastoma Guidelines Writing Committee. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer. 2013;60:719–27.

Article  PubMed  Google Scholar 

Kaliki S, Shields CL, Eagle RC Jr, Iram S, Shields JA. High-risk intraocular retinoblastoma: comparison between Asian Indians and Americans from two major referral centers. Retina. 2018;38:2023–9.

Article  PubMed  Google Scholar 

Kashyap S, Meel R, Pushker N, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr Blood Cancer. 2012;58:356–61.

Article  PubMed  Google Scholar 

Kashyap S, Sethi S, Meel R, et al. A histopathologic analysis of eyes primarily enucleated for advanced intraocular retinoblastoma from a developing country. Arch Pathol Lab Med. 2012;136:190–3.

Article  PubMed  Google Scholar 

Sastre X, Chantada GL, Doz F, et al; International Retinoblastoma Staging Working Group. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133:1199–202.

Article  PubMed  Google Scholar 

Kashyap S, Singh L, Kumar N, et al. Combined association of massive choroidal and optic nerve invasion as a prognostic relevance in primary retinoblastoma: a 10-year study. Asia Pac J Clin Oncol. 2021;17:e100–8.

Article  PubMed  Google Scholar 

Messmer EP, Heinrich T, Höpping W, de Sutter E, Havers W, Sauerwein W. Risk factors for metastasis in patients with retinoblastoma. Ophthalmology. 1991;98:136–41.

Article  CAS  PubMed  Google Scholar 

Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923–31.

Article  PubMed  Google Scholar 

Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129:1422–7.

Article  CAS  PubMed  Google Scholar 

Ye H, Du Y, Chen R, et al. The potential benefit of three vs. six cycles of carboplatin, etoposide, and vincristine in post enucleation high-risk patients with IRSS stage I retinoblastoma. Curr Eye Res. 2016;41:1507–12.

Article  CAS